FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Craig Brater

Research Profile

Chemicals & Drugs

Disorders

Anatomy

Kidneys

Physiology

Procedures

Geographic Areas

Indiana

Concepts & Ideas

Drug Dose Response Relationship

Co-author Network

Publications

TOP 3
Henry Krum; Loren Laine; Paul M Peloso; Steven S Smugar; Gary Swergold; Hongwei Wang; Matthew R Weir; D Craig Brater; Sean P Curtis; Arnold Gammaitoni; Amarjot Kaur; Christopher P Cannon
Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs.
Kye-Min Kim; Michael D Murray; Jason Robarge; Wanzhu Tu; D Craig Brater; Yan Ding; David A Flockhart
Pharmacogenetics and healthcare outcomes in patients with chronic heart failure.
Matthew J Matava; Douglas Rollins; Theodore Schlegel; Robert Toto; D Craig Brater; Nancy Gritter; Robert Heyer; Anthony Yates
Recommendations of the national football league physician society task force on the use of toradol(®) ketorolac in the national football league.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Craig Brater (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Henry Krum; Loren Laine; Paul M Peloso; Steven S Smugar; Gary Swergold; Hongwei Wang; Matthew R Weir; D Craig Brater; Sean P Curtis; Arnold Gammaitoni; Amarjot Kaur; Christopher P Cannon
Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs.
Cardiovascular therapeutics 2012;30(6):342-50.
2012: Kye-Min Kim; Michael D Murray; Jason Robarge; Wanzhu Tu; D Craig Brater; Yan Ding; David A Flockhart
Pharmacogenetics and healthcare outcomes in patients with chronic heart failure.
European journal of clinical pharmacology 2012;68(11):1483-91.
2012: Matthew J Matava; Douglas Rollins; Theodore Schlegel; Robert Toto; D Craig Brater; Nancy Gritter; Robert Heyer; Anthony Yates
Recommendations of the national football league physician society task force on the use of toradol(®) ketorolac in the national football league.
Sports health 2012;4(5):377-83.
2012: Hisham Aljadhey; Susan J Blalock; D Craig Brater; Richard A Hansen; Wanzhu Tu; Michael D Murray
Comparative effects of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension.
BMC cardiovascular disorders 2012;12():93.
2011: D Craig Brater
Update in diuretic therapy: clinical pharmacology.
Seminars in nephrology 2011;31(6):483-94.
2011: Anantha Shekhar; Scott Denne; William Tierney; David Wilkes; D Craig Brater
A model for engaging public-private partnerships.
Clinical and translational science 2011;4(2):80-3.
2010: Hisham Aljadhey; Wanzhu Tu; Richard A Hansen; Susan Blalock; D Craig Brater; Michael D Murray
Risk of hyperkalemia associated with selective COX-2 inhibitors.
Pharmacoepidemiology and drug safety 2010;19(11):1194-8.
2009: D Craig Brater
Drug dosing in patients with impaired renal function.
Clinical pharmacology and therapeutics 2009;86(5):483-9.
2009: Kevin J Leary; Michael A Riel; Michael Roy; Louis R Cantilena; Daoqin Bi; D Craig Brater; Corina van de Pol; Khadeeja Pruett; Caron Kerr; James M Veazey; Ronnie Beboso; Colin Ohrt
A randomized, double-blind, safety and tolerability study to assess the ophthalmic and renal effects of tafenoquine 200 mg weekly versus placebo for 6 months in healthy volunteers.
The American journal of tropical medicine and hygiene 2009;81(2):356-62.
2009: Henry Krum; Sean P Curtis; Amarjot Kaur; Hongwei Wang; Steven S Smugar; Matthew R Weir; Loren Laine; D Craig Brater; Christopher P Cannon
Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program.
European journal of heart failure 2009;11(6):542-50.
2009: Henry Krum; Gary Swergold; Sean P Curtis; Amarjot Kaur; Hongwei Wang; Steven S Smugar; Matthew R Weir; Loren Laine; D Craig Brater; Christopher P Cannon
Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study.
Journal of hypertension 2009;27(4):886-93.
2007: D Craig Brater
Viewpoint: infusing professionalism into a school of medicine: perspectives from the dean.
Academic medicine : journal of the Association of American Medical Colleges 2007;82(11):1094-7.
2007: Michael D Murray; James Young; Shawn Hoke; Wanzhu Tu; Michael Weiner; Daniel Morrow; Kevin T Stroupe; Jingwei Wu; Daniel Clark; Faye Smith; Irmina Gradus-Pizlo; Morris Weinberger; D Craig Brater
Pharmacist intervention to improve medication adherence in heart failure: a randomized trial.
Annals of internal medicine 2007;146(10):714-25.
2005: Susan J Bennett; Kathleen A Lane; Janet Welch; Susan M Perkins; D Craig Brater; Michael D Murray
Medication and dietary compliance beliefs in heart failure.
Western journal of nursing research 2005;27(8):977-93; discussion 994-9.
2005: Gunilla Huledal; Bror Jonzon; Maria Malmenäs; Ann Hedman; Lars I Andersson; Bo Odlind; D Craig Brater
Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake.
Clinical pharmacology and therapeutics 2005;77(5):437-50.
2005: Wanzhu Tu; Andrew B Morris; Jingjin Li; Jingwei Wu; James Young; D Craig Brater; Michael D Murray
Association between adherence measurements of metoprolol and health care utilization in older patients with heart failure.
Clinical pharmacology and therapeutics 2005;77(3):189-201.
2004: Robert J MacFadyen; Gorski Jan; D Craig Brater; Allan D Struthers
Furosemide responsiveness, non-adherence and resistance during the chronic treatment of heart failure: a longitudinal study.
British journal of clinical pharmacology 2004;57(5):622-31.
2004: Kevin T Stroupe; Evgenia Y Teal; Michael Weiner; Irmina Gradus-Pizlo; D Craig Brater; Michael D Murray
Health care and medication costs and use among older adults with heart failure.
The American journal of medicine 2004;116(7):443-50.
2004: Michael D Murray; James M Young; Daniel G Morrow; Michael Weiner; Wanzhu Tu; Shawn C Hoke; Daniel O Clark; Kevin T Stroupe; Jingwei Wu; Melissa Deer; Tina E Bruner-England; Kevin M Sowinski; Faye E Smith; Neil B Oldridge; Irmina Gradus-Pizlo; Laura L Murray; D Craig Brater; Morris Weinberger
Methodology of an ongoing, randomized, controlled trial to improve drug use for elderly patients with chronic heart failure.
The American journal of geriatric pharmacotherapy 2004;2(1):53-65.
2004: Michael D Murray; Daniel G Morrow; Michael Weiner; Daniel O Clark; Wanzhu Tu; Melissa Deer; D Craig Brater; Morris Weinberger
A conceptual framework to study medication adherence in older adults.
The American journal of geriatric pharmacotherapy 2004;2(1):36-43.
2004: William R Hiatt; Alan T Hirsch; john cooke; Jeffrey W Olin; D Craig Brater; Mark A Creager
Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacy.
Vascular medicine (London, England) 2004;9(1):18-25.
2003: Michelle A Chui; Melissa Deer; Susan J Bennett; Wanzhu Tu; Stacey Oury; D Craig Brater; Michael D Murray
Association between adherence to diuretic therapy and health care utilization in patients with heart failure.
Pharmacotherapy 2003;23(3):326-32.
2003: Sudha S Shankar; D Craig Brater
Loop diuretics: from the Na-K-2Cl transporter to clinical use.
American journal of physiology. Renal physiology 2003;284(1):F11-21.
2002: D Craig Brater
Anti-inflammatory agents and renal function.
Seminars in arthritis and rheumatism 2002;32(3 Suppl 1):33-42.
2002: Lee S Simon; Josef S Smolen; Steven B Abramson; Gerald Appel; Claire Bombardier; D Craig Brater; Ferdinand C Breedveld; K Brune; Gerd R Burmester; Leslie J Crofford; Maxime Dougados; Raymond DuBois; garret fitzgerald; W Frishman; Luis A García Rodríguez; Marc C Hochberg; Joachim R Kalden; Loren Laine; M J S Langman; Stephen M Prescott; L B A Van De Putte; Andrew Whelton; William B White; Gordon H Willaims
Controversies in COX-2 selective inhibition.
The Journal of rheumatology 2002;29(7):1501-10.
2002: D Craig Brater
Measurement of renal function during drug development.
British journal of clinical pharmacology 2002;54(1):87-95.
2002: D Craig Brater
Renal effects of cyclooxygyenase-2-selective inhibitors.
Journal of pain and symptom management 2002;23(4 Suppl):S15-20; discussion S21-3.
2002: Stephen S Gottlieb; D Craig Brater; Ignatius Thomas; Edward Havranek; Robert Bourge; Steven Goldman; Farere Dyer; Miguel Gomez; Donald Bennett; Barry Ticho; Evan Beckman; William T Abraham
BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy.
Circulation 2002;105(11):1348-53.
2001: Michael D Murray; Melissa Deer; J A Ferguson; Paul R Dexter; S J Bennett; Susan M Perkins; Faye E Smith; Kathleen A Lane; L D Adams; William M Tierney; D Craig Brater
Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure.
The American journal of medicine 2001;111(7):513-20.
2001: C J Harris; D Craig Brater
Renal effects of cyclooxygenase-2 selective inhibitors.
Current opinion in nephrology and hypertension 2001;10(5):603-10.
2001: S J Bennett; Susan M Perkins; Kathleen A Lane; M A Forthofer; D Craig Brater; Michael D Murray
Reliability and validity of the compliance belief scales among patients with heart failure.
Heart & lung : the journal of critical care 2001;30(3):177-85.
2001: Naga Chalasani; Gorski Jan; JC Horlander; R Craven; H Hoen; Juan F Maya; D Craig Brater
Effects of albumin/furosemide mixtures on responses to furosemide in hypoalbuminemic patients.
Journal of the American Society of Nephrology : JASN 2001;12(5):1010-6.
2001: Susan J Bennett; Susan M Perkins; Kathleen A Lane; Melissa Deer; D Craig Brater; Michael D Murray
Social support and health-related quality of life in chronic heart failure patients.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2001;10(8):671-82.
2001: D Craig Brater; Naga Chalasani; Gorski Jan; JC Horlander; R Craven; H Hoen; Juan F Maya
Effect of albumin-furosemide mixtures on response to furosemide in cirrhotic patients with ascites.
Transactions of the American Clinical and Climatological Association 2001;112():108-15; discussion 116.
2001: D Craig Brater; C Harris; Jan S Redfern; B J Gertz
Renal effects of COX-2-selective inhibitors.
American journal of nephrology 2001;21(1):1-15.
2000: Andrew L Masica; N E Azie; D Craig Brater; Stephen D Hall; David R Jones
Intravenous diltiazem and CYP3A-mediated metabolism.
British journal of clinical pharmacology 2000;50(3):273-6.
2000: Suzanne K Swan; DW Rudy; K C Lasseter; C F Ryan; K L Buechel; Larry Lambrecht; M B Pinto; Stacy C Dilzer; O Obrda; KJ Sundblad; C P Gumbs; David L Ebel; H Quan; Patrick J Larson; Jules I Schwartz; T A Musliner; B J Gertz; D Craig Brater; S L Yao
Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial.
Annals of internal medicine 2000;133(1):1-9.
2000: Rajiv Agarwal; Gorski Jan; KJ Sundblad; D Craig Brater
Urinary protein binding does not affect response to furosemide in patients with nephrotic syndrome.
Journal of the American Society of Nephrology : JASN 2000;11(6):1100-5.
2000: Kevin T Stroupe; M M Forthofer; D Craig Brater; Michael D Murray
Healthcare costs of patients with heart failure treated with torasemide or furosemide.
PharmacoEconomics 2000;17(5):429-40.
2000: D Craig Brater; WJ Daly
Clinical pharmacology in the Middle Ages: principles that presage the 21st century.
Clinical pharmacology and therapeutics 2000;67(5):447-50.
2000: O Mousa; D Craig Brater; K J Sunblad; Stephen D Hall
The interaction of diltiazem with simvastatin.
Clinical pharmacology and therapeutics 2000;67(3):267-74.
2000: WJ Daly; D Craig Brater
Medieval contributions to the search for truth in clinical medicine.
Perspectives in biology and medicine 2000;43(4):530-40.
2000: D Craig Brater
Pharmacology of diuretics.
The American journal of the medical sciences 2000;319(1):38-50.
1999: D Craig Brater
Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition.
The American journal of medicine 1999;107(6A):65S-70S; discussion 70S-71S.
1999: D Craig Brater
Use of diuretics in cirrhosis and nephrotic syndrome.
Seminars in nephrology 1999;19(6):575-80.
1999: N G Grubb; DW Rudy; D Craig Brater; Stephen D Hall
Stereoselective pharmacokinetics of ketoprofen and ketoprofen glucuronide in end-stage renal disease: evidence for a 'futile cycle' of elimination.
British journal of clinical pharmacology 1999;48(4):494-500.
1998: N E Azie; D Craig Brater; P A Becker; David R Jones; Stephen D Hall
The interaction of diltiazem with lovastatin and pravastatin.
Clinical pharmacology and therapeutics 1998;64(4):369-77.
1998: D Craig Brater
Diuretic therapy.
The New England journal of medicine 1998;339(6):387-95.
1998: Michael D Murray; W M Tierney; D Craig Brater
Determining the effectiveness of torasemide and furosemide in heart failure: design of a randomised comparison using the regenstrief medical record system.
Clinical drug investigation 1998;16(1):45-52.
1997: J A Ferguson; KJ Sundblad; P K Becker; Gorski Jan; DW Rudy; D Craig Brater
Role of duration of diuretic effect in preventing sodium retention.
Clinical pharmacology and therapeutics 1997;62(2):203-8.
1997: Michael D Murray; E N Lazaridis; E Brizendine; KM Haag; P Becker; D Craig Brater
The effect of nonsteroidal antiinflammatory drugs on electrolyte homeostasis and blood pressure in young and elderly persons with and without renal insufficiency.
The American journal of the medical sciences 1997;314(2):80-8.
1997: Michael D Murray; D Craig Brater
Effects of NSAIDs on the kidney.
Progress in drug research. Fortschritte der Arzneimittelforschung. Progrès des recherches pharmaceutiques 1997;49():155-71.
1997: Michael D Murray; KM Haag; P K Black; S D Hall; D Craig Brater
Variable furosemide absorption and poor predictability of response in elderly patients.
Pharmacotherapy 1997;17(1):98-106.
1996: D L Vargo; D Craig Brater; DW Rudy; S K Swan
Dopamine does not enhance furosemide-induced natriuresis in patients with congestive heart failure.
Journal of the American Society of Nephrology : JASN 1996;7(7):1032-7.
1996: W G Kramer; W B Smith; J Ferguson; T Serpas; A G Grant; P K Black; D Craig Brater
Pharmacodynamics of torsemide administered as an intravenous injection and as a continuous infusion to patients with congestive heart failure.
Journal of clinical pharmacology 1996;36(3):265-70.
1995: Michael D Murray; P K Black; D D Kuzmik; K M Haag; A K Manatunga; M A Mullin; Stephen D Hall; D Craig Brater
Acute and chronic effects of nonsteroidal antiinflammatory drugs on glomerular filtration rate in elderly patients.
The American journal of the medical sciences 1995;310(5):188-97.
1995: D L Vargo; W G Kramer; P K Black; W B Smith; T Serpas; D Craig Brater
Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure.
Clinical pharmacology and therapeutics 1995;57(6):601-9.
1995: A C Rudy; P M Knight; D Craig Brater; Stephen D Hall
Enantioselective disposition of ibuprofen in elderly persons with and without renal impairment.
The Journal of pharmacology and experimental therapeutics 1995;273(1):88-93.
1994: D Craig Brater
The use of diuretics in congestive heart failure.
Seminars in nephrology 1994;14(5):479-84.
1994: D Vargo; W G Kramer; P K Black; W B Smith; T Serpas; D Craig Brater
The pharmacodynamics of torsemide in patients with congestive heart failure.
Clinical pharmacology and therapeutics 1994;56(1):48-54.
1994: DW Rudy; Todd W B Gehr; G R Matzke; W G Kramer; Domenic A Sica; D Craig Brater
The pharmacodynamics of intravenous and oral torsemide in patients with chronic renal insufficiency.
Clinical pharmacology and therapeutics 1994;56(1):39-47.
1994: Todd W B Gehr; DW Rudy; G R Matzke; W G Kramer; Domenic A Sica; D Craig Brater
The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency.
Clinical pharmacology and therapeutics 1994;56(1):31-8.
1994: Timothy S Tracy; T Worster; J D Bradley; P K Greene; D Craig Brater
Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis.
British journal of clinical pharmacology 1994;37(5):453-6.
1994: A C Rudy; N L Figueroa; Stephen D Hall; D Craig Brater
The pharmacokinetics of piroxicam in elderly persons with and without renal impairment.
British journal of clinical pharmacology 1994;37(1):1-5.
1994: D Craig Brater
Diuretic resistance: mechanisms and therapeutic strategies.
Cardiology 1994;84 Suppl 2():57-67.
1993: S Schwartz; D Craig Brater; D Pound; P K Green; W G Kramer; DW Rudy
Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis.
Clinical pharmacology and therapeutics 1993;54(1):90-7.
1993: Stephen D Hall; A C Rudy; P M Knight; D Craig Brater
Lack of presystemic inversion of (R)- to (S)-ibuprofen in humans.
Clinical pharmacology and therapeutics 1993;53(4):393-400.
1993: D Craig Brater; D R Rudy; J R Voelker; P K Greene; Todd W B Gehr; Domenic A Sica
Pharmacokinetics and pharmacodynamics of torasemide in patients with chronic renal insufficiency--preliminary evaluation.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 1993;7 Suppl 1():69-73.
1993: D Craig Brater
Resistance to diuretics: mechanisms and clinical implications.
Advances in nephrology from the Necker Hospital 1993;22():349-69.
1992: D Craig Brater
Clinical pharmacology of loop diuretics in health and disease.
European heart journal 1992;13 Suppl G():10-4.
1992: Michael D Murray; P K Greene; D Craig Brater; A K Manatunga; Stephen D Hall
Effects of flurbiprofen on renal function in patients with moderate renal insufficiency.
British journal of clinical pharmacology 1992;33(4):385-93.
1992: M P Knadler; D Craig Brater; Stephen D Hall
Stereoselective disposition of flurbiprofen in uraemic patients.
British journal of clinical pharmacology 1992;33(4):377-83.
1992: M P Knadler; D Craig Brater; Stephen D Hall
Stereoselective disposition of flurbiprofen in normal volunteers.
British journal of clinical pharmacology 1992;33(4):369-75.
1992: Timothy S Tracy; K Krohn; D R Jones; J D Bradley; Stephen D Hall; D Craig Brater
The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis.
European journal of clinical pharmacology 1992;42(2):121-5.
1992: J D Bradley; A C Rudy; Barry P Katz; S I Ryan; L A Kalasinski; D Craig Brater; Stephen D Hall; Kenneth D Brandt
Correlation of serum concentrations of ibuprofen stereoisomers with clinical response in the treatment of hip and knee osteoarthritis.
The Journal of rheumatology 1992;19(1):130-4.
1991: A C Rudy; P M Knight; D Craig Brater; Stephen D Hall
Stereoselective metabolism of ibuprofen in humans: administration of R-, S- and racemic ibuprofen.
The Journal of pharmacology and experimental therapeutics 1991;259(3):1133-9.
1991: C Tsao; P Greene; B Odlind; D Craig Brater
Pharmacokinetics of recombinant human superoxide dismutase in healthy volunteers.
Clinical pharmacology and therapeutics 1991;50(6):713-20.
1991: D W Rudy; J R Voelker; P K Greene; F A Esparza; D Craig Brater
Loop diuretics for chronic renal insufficiency: a continuous infusion is more efficacious than bolus therapy.
Annals of internal medicine 1991;115(5):360-6.
1991: M J Fredrick; D C Pound; Stephen D Hall; D Craig Brater
Furosemide absorption in patients with cirrhosis.
Clinical pharmacology and therapeutics 1991;49(3):241-7.
1991: D Craig Brater
Clinical pharmacology of loop diuretics.
Drugs 1991;41 Suppl 3():14-22.
1990: D Craig Brater
Clinical pharmacology: where has the support gone?
Clinical pharmacology and therapeutics 1990;48(3):219-24.
1990: D Craig Brater
Future of the American Society for Clinical Pharmacology and Therapeutics.
Clinical pharmacology and therapeutics 1990;47(2):299-301.
1989: J R Voelker; David Jameson; D Craig Brater
In vitro evidence that urine composition affects the fraction of active furosemide in the nephrotic syndrome.
The Journal of pharmacology and experimental therapeutics 1989;250(3):772-8.
1989: M P Knadler; D Craig Brater; Stephen D Hall
Plasma protein binding of flurbiprofen: enantioselectivity and influence of pathophysiological status.
The Journal of pharmacology and experimental therapeutics 1989;249(2):378-85.
1988: D Craig Brater
Use of diuretics in chronic renal insufficiency and nephrotic syndrome.
Seminars in nephrology 1988;8(4):333-41.
1988: D Craig Brater
Clinical pharmacology of NSAIDs.
Journal of clinical pharmacology 1988;28(6):518-23.
1987: J R Voelker; D Cartwright-Brown; S Anderson; J Leinfelder; Domenic A Sica; J P Kokko; D Craig Brater
Comparison of loop diuretics in patients with chronic renal insufficiency.
Kidney international 1987;32(4):572-8.